- Home
- ATOS vs UNCY Comparison
ATOS vs UNCY Comparison
Compare ATOS & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- UNCY
- Stock Information
- Founded
- ATOS 2009
- UNCY 2016
- Country
- ATOS United States
- UNCY United States
- Employees
- ATOS N/A
- UNCY N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- ATOS Health Care
- UNCY Health Care
- Exchange
- ATOS Nasdaq
- UNCY Nasdaq
- Market Cap
- ATOS 112.5M
- UNCY 91.0M
- IPO Year
- ATOS 2012
- UNCY 2021
- Fundamental
- Price
- ATOS $0.85
- UNCY $4.55
- Analyst Decision
- ATOS Strong Buy
- UNCY Strong Buy
- Analyst Count
- ATOS 3
- UNCY 4
- Target Price
- ATOS $6.17
- UNCY $63.75
- AVG Volume (30 Days)
- ATOS 1.5M
- UNCY 1.5M
- Earning Date
- ATOS 08-11-2025
- UNCY 08-13-2025
- Dividend Yield
- ATOS N/A
- UNCY N/A
- EPS Growth
- ATOS N/A
- UNCY N/A
- EPS
- ATOS N/A
- UNCY N/A
- Revenue
- ATOS N/A
- UNCY N/A
- Revenue This Year
- ATOS N/A
- UNCY N/A
- Revenue Next Year
- ATOS N/A
- UNCY $1,458.53
- P/E Ratio
- ATOS N/A
- UNCY N/A
- Revenue Growth
- ATOS N/A
- UNCY N/A
- 52 Week Low
- ATOS $0.55
- UNCY $2.02
- 52 Week High
- ATOS $1.66
- UNCY $11.00
- Technical
- Relative Strength Index (RSI)
- ATOS 51.17
- UNCY 39.53
- Support Level
- ATOS $0.81
- UNCY $4.76
- Resistance Level
- ATOS $0.92
- UNCY $7.15
- Average True Range (ATR)
- ATOS 0.05
- UNCY 0.97
- MACD
- ATOS -0.00
- UNCY -0.28
- Stochastic Oscillator
- ATOS 52.73
- UNCY 7.37
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.